© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Hybrid

Top Section/Ad

Top Section/Ad

Most recent


◆ Books grow during pricing ◆ Geopolitical volatility does not derail hybrid deal ◆ Trade prices through fair value, tight to senior
◆ Hybrid books hold firm as senior sales shed ◆ Both tranches land far through fair value ◆ Telefónica achieves tight senior/sub spreads
◆ Peak demand reaches €11.5bn ◆ Longer call tightened harder than the short tranche ◆ Both tranches priced close to fair value
Hybrid bonds remain very rare from the Gulf
More articles/Ad

More articles/Ad

More articles

  • German utility company ENBW completed a $300m dollar hybrid bond deal on Monday, attracting 119 Asian and European accounts eager to increase their holdings of the product, despite volatility in euro markets.
  • The grins on the faces of Werner Baumann and Hugh Grant, chief executives of Bayer and Monsanto, look genuine enough. The deal they have struck could catapult Baumann to head of the world’s leading agribusiness company and net Grant a reported $226m.
  • Spanish telecoms provider Telefónica latched onto the swell of investor demand for riskier corners of the European investment grade corporate bond market on Thursday as it issued a €1bn hybrid bond.
  • A lacklustre year for equity capital markets suddenly grew more interesting on Monday, when Bayer announced the details of a $62bn bid for Monsanto. It got still more interesting on Tuesday, when the US agribusiness group rejected the offer as “incomplete and financially inadequate”.
  • Monsanto has rejected Bayer’s all-cash bid of a $62bn enterprise value as “incomplete and financially inadequate”, but left the door open to an improved offer.
  • Bayer could be preparing to issue one of the five biggest rights issues ever, and the largest by a non-bank company, as part of the financing for its $62bn bid for Monsanto, the US agricultural chemicals and bio-engineering business.